Pharmacology Books

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

Drug Design by Jr

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

Book SynopsisThis essential and concise clinical reference guide serves diverse clinicians and allied health professionals who prescribe antiepileptic drugs in contemporary clinical practice. Fully updated, it features chapters on newly-approved drug brivaracetam, updated paediatric prescribing, use in particular populations including women, the elderly, and patients with cognitive impairment, as well as sections on teratogenicity, pregnancy, and lactation. In full colour throughout, the guide provides comprehensive antiepileptic drug (AED) prescribing information, covering all thirty-five AEDs in alphabetical order. Each chapter features eight coloured sections including general therapeutics, pharmacokinetics, interaction profile, adverse effects, dosing and use, special population considerations, a summary overview, and suggested reading. Perfect for quick reference use, the guide is practical and essential for all AED drug prescribers including adult and paediatric neurologists, neurosurgeons, pTable of Contents1. Acetazolamide; 2. ACTH; 3. Brivaracetam; 4. Carbamazepine; 5. Clobazam; 6. Clonazepam; 7. Diazepam; 8. Eslicarbazepine; 9. Ethosuximide; 10. Felbamate; 11. Fosphenytoin; 12. Gabapentin; 13. Lacosamide; 14. Lamotrigine; 15. Levetiracetam; 16. Lorazepam; 17. Methsuximide; 18. Midazolam; 19. Oxcarbazepine; 20. Paraldehyde; 21. Perampanel; 22. Phenobarbital; 23. Phenytoin; 24. Piracetam; 25. Pregabalin; 26. Primidone; 27. Rufinamide; 28. Stiripentol; 29. Sulthiame; 30. Tiagabine; 31. Topiramate; 32. Valproate; 33. Vigabatrin; 34. Zonasimide.

Read more less

Book SynopsisA review of the scientific evidence on the effects of cannabinoids on brain and behavioral functioning, with an emphasis on potential therapeutic use.The cannabis plant has been used for recreational and medicinal purposes for more than 4,000 years, but the scientific investigation into its effects has only recently yielded useful results. In this book, Linda Parker offers a review of the scientific evidence on the effects of cannabinoids on brain and behavioral functioning, with an emphasis on potential therapeutic uses.Parker describes the discovery of tetrahydocannbinol (THC), the main psychoactive component of cannabis, and the further discovery of cannabinoid receptors in the brain. She explains that the brain produces chemicals similar to THC, which act on the same receptors as THC, and shows that the endocannabinoid system is involved in all aspects of brain functioning. Parker reports that cannabis contains not only the psychoactive compound THC, but also

Read more less

Book SynopsisTable of ContentsUNIT I: General Aspects of Pharmacology 1. Drug Regulation, Actions, and Responses 2. Safely Preparing and Giving Drugs UNIT II: Mathematics for Pharmacology and Dosage Calculation 3. Mathematics Review and Introduction to Dosage Calculations 4. Medical Systems of Weights and Measures 5. Dosage Calculation of Intravenous Solutions and Drugs UNIT III: Pharmacology For Multisystem Application 6. Anti-Inflammatory Drugs 7. Drugs for Pain Control 8. Anti-Infectives: Antibacterial Drugs 9. Anti-Infectives: Antiviral Drugs 10. Anti-Infectives: Antitubercular and Antifungal Drugs 11. Immunizations 12. Anticancer Drugs Unit IV: Drug Therapy for Endocrine Problems 13. Drug therapy for Diabetes 14. Drug Therapy for Thyroid and Adrenal Gland Problems Unit V: Drug Therapy for Problems of the Circulatory and Cardiac Systems 15. Drug Therapy Affecting Urine Output 16. Drug Therapy for Hypertension 17. Drug Therapy for Heart Failure 18. Drug Therapy for Dysrhythmias 19. Drug Therapy for High Blood Lipids 20. Drug Therapy to Disrupt Clotting Unit VI: Drug Therapy for Respiratory System Problems 21. Drug Therapy for Asthma, Chronic Obstructive Pulmonary Disease, and Pulmonary Fibrosis/Hypertension Unit VII: Drug Therapy for Gastrointestinal System Problems 22. Drug Therapy for Gastrointestinal Dysfunction 23. Drug Therapy for Gastric Ulcers and Reflux 24. Drug Therapy with Nutritional Supplements Unit VIII: Drug Therapy for Nervous System Problems 25. Drug Therapy for Seizures 26. Drug Therapy for Parkinson's and Alzheimer's Diseases 27. Drug Therapy for Psychiatric Problems 28. Drug Therapy for Insomnia 29. Drug Therapy for Eye Problems Unit IX: Drug Therapy for Problems of the Musculoskeletal System 30. Drug Therapy for Osteoporosis and Muscle Relaxation Unit X: Drug Therapy for Problems of the Reproductive System 31. Drug Therapy for Male Reproductive Problems 32. Drug Therapy for Female Reproductive Problems Glossary Index

Read more less

Book Synopsis

Read more less

Book Synopsis

Read more less

Book Synopsis

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

Book SynopsisCancer vaccine development has changed from a small-scale academic enterprise in to an applied science requiring a large, clinical-research infrastructure. Cancer Vaccines and Tumor Immunity will serve a unique role in that it will present as a continuum the basic science discoveries that have moved forward into clinical trials.Table of ContentsContributors. Foreword. Cancer Vaccines and Cancer Immunotherapy. A New Paradigm(Jeffrey Schlom). PART I. INTRODUCTION. Chapter 1. Cancer Vaccines. Progress and Promise (Rimas J. Orentas, Bryon Johnson, and James Hodge). PART II. ADJUVANT THERAPY: ENHANCING THE ENDOGENOUS IMMUNE RESPONSE. Chapter 2. Fully Synthetic Carbohydrate-Based Anti-Tumor Vaccines (Rebecca M. Wilson and Samuel J. Danishefsky). Chapter 3. Bacillus Calmette-Guerin Immunotherapy of Genitourinary Cancer (Donald L. Lamm). Chapter 4. Stimulation of Toll-like Receptor 9 for Enhancing Vaccination (Daniel E. Speiser and Arthur M. Krieg). PART III. ANTIGEN-SPECIFIC THERAPY: NOVEL PRESENTATION OF PEPTIDE AND PROTEIN ANTIGENS. Chapter 5. Polyepitope Vaccines (Corey Smith and Rajiv Khanna). Chapter 6. Antigen-Specific Cancer Immunotherapy: HPV-Associated Cervical Cancer as a Model System (Shaw-Wei D. Tsen, Chien-Fu Hung, and T.-C. Wu). Chapter 7. Poxviral Vectors for Cancer Vaccines: State of the Art (Elizabeth K. Wansley). Chapter 8. Immunotherapeutic Strategies Against Cancer Using Listeria Monocytogenes as a Vector for Tumor Antigens (Nicholas C. Souders, Thorsten Verch and Yvonne Paterson). Chapter 9. Coupling Innate and Adaptive Immunity with Yeast-based Cancer Immunotherapy (Sibyl Munson, Joanne Parker, Tom King, Yingnian Lu, Victoria Kelley, Zhimin Guo, Virginia Borges, and Alex Franzusoff). PART IV. CELL-BASED THERAPY: USING CANCER CELLS AS A MEANS TO INDUCE SPECIFIC TUMOR IMMUNITY. Chapter 10. Allogeneic Whole Cell Vaccines (John Copier and Angus Dalgleish). Chapter 11. Jump-Starting Tumor Immunity with Breast Cancer Therapeutics (Leisha A. Emens). Chapter 12. T-Regulatory Cell Manipulation in Tumor Immunotherapy (Jens Rüter, Brian G. Barnett, Ilona Kryczek, Michael J. Brumlik, Benjamin J. Daniel, George Coukos, Weiping Zou, Tyler J. Curiel). Chapter 13. Tumor Vaccination after Autologous HSCT: What has been Learned from Experimental Models? (Weiqing Jing and Bryon D. Johnson). Chapter 14. Vaccines in the Setting of Hematopoietic Stem Cell Transplantation (Ronald Gress and Claude Sportes). Chapter 15. Intratumor Generation of Vigorous Antitumor Immune Responses (Ping Yu and Yang-Xin Fu). Chapter 16. Cancer Immunotherapy: Untapping the Potential of Co-Stimulatory Molecules Beyond CTLA-4 (Mathew Augustine, and Lieping Chen). PART V. DEFINING EFFECTIVE CLINICAL RESPONSES. Chapter 17. Advances in Immune Monitoring Strategies for Cancer Vaccines and Immunotherapy (Seunghee Kim-Schulze, Moshe Ornstein and Howard L. Kaufman). Chapter 18. Immune Evaluation of Cancer Vaccines (Theresa L. Whiteside). Index.

Read more less

Book SynopsisAntibacterial agents act against bacterial infection either by killing the bacterium or by arresting its growth. They do this by targeting bacterial DNA and its associated processes, attacking bacterial metabolic processes including protein synthesis, or interfering with bacterial cell wall synthesis and function. Antibacterial Agents is an essential guide to this important class of chemotherapeutic drugs. Compounds are organised according to their target, which helps the reader understand the mechanism of action of these drugs and how resistance can arise. The book uses an integrated lab-to-clinic approach which covers drug discovery, source or synthesis, mode of action, mechanisms of resistance, clinical aspects (including links to current guidelines, significant drug interactions, cautions and contraindications), prodrugs and future improvements. Agents covered include: agents targeting DNA - quinolone, rifamycin, and nitroimidazole Table of ContentsPreface xiii SECTION 1 INTRODUCTION TO MICROORGANISMS AND ANTIBACTERIAL CHEMOTHERAPY 1 1.1 Microorganisms 3 Key points 3 1.1.1 Classification 3 1.1.2 Structure 4 1.1.3 Antibacterial targets 6 1.1.4 Bacterial detection and identification 17 1.1.5 Other than its mode of action, what factors determine the antibacterial activity of a drug? 25 1.1.6 Bacterial resistance 27 1.1.7 The ‘post-antibiotic age’? 29 References 31 Questions 33 SECTION 2 AGENTS TARGETING DNA 35 2.1 Quinolone antibacterial agents 37 Key points 37 2.1.1 Discovery 37 2.1.2 Synthesis 39 2.1.3 Bioavailability 41 2.1.4 Mode of action and selectivity 44 2.1.5 Bacterial resistance 45 2.1.6 Clinical applications 47 2.1.7 Adverse drug reactions 50 2.1.8 Drug interactions 55 2.1.9 Recent developments 56 References 60 2.2 Rifamycin antibacterial agents 63 Key points 63 2.2.1 Discovery 63 2.2.2 Synthesis 65 2.2.3 Bioavailability 68 2.2.4 Mode of action and selectivity 69 2.2.5 Bacterial resistance 71 2.2.6 Clinical applications 71 2.2.7 Adverse drug reactions 77 2.2.8 Drug interactions 78 2.2.9 Recent developments 81 References 81 2.3 Nitroimidazole antibacterial agents 85 Key points 85 2.3.1 Discovery 85 2.3.2 Synthesis 86 2.3.3 Bioavailability 86 2.3.4 Mode of action and selectivity 87 2.3.5 Mechanisms of resistance 89 2.3.6 Clinical applications 90 2.3.7 Adverse drug reactions 94 2.3.8 Drug interactions 95 2.3.9 Recent developments 96 References 97 Questions 101 SECTION 3 AGENTS TARGETING METABOLIC PROCESSES 103 3.1 Sulfonamide antibacterial agents 105 Key points 105 3.1.1 Discovery 105 3.1.2 Synthesis 107 3.1.3 Bioavailability 108 3.1.4 Mode of action and selectivity 111 3.1.5 Bacterial resistance 114 3.1.6 Clinical applications 115 3.1.7 Adverse drug reactions 119 3.1.8 Drug interactions 121 3.1.9 Recent developments 123 References 124 3.2 Trimethoprim 127 Key points 127 3.2.1 Discovery 127 3.2.2 Synthesis 128 3.2.3 Bioavailability 130 3.2.4 Mode of action and selectivity 130 3.2.5 Bacterial resistance 136 3.2.6 Clinical applications 136 3.2.7 Adverse drug reactions 138 3.2.8 Drug interactions 138 3.2.9 Recent developments 139 References 140 Questions 145 SECTION 4 AGENTS TARGETING PROTEIN SYNTHESIS 147 4.1 Aminoglycoside antibiotics 149 Key points 149 4.1.1 Discovery 149 4.1.2 Synthesis 152 4.1.3 Bioavailability 156 4.1.4 Mode of action and selectivity 158 4.1.5 Bacterial resistance 160 4.1.6 Clinical applications 161 4.1.7 Adverse drug reactions 165 4.1.8 Drug interactions 167 4.1.9 Recent developments 168 References 168 4.2 Macrolide antibiotics 173 Key points 173 4.2.1 Discovery 173 4.2.2 Synthesis 175 4.2.3 Bioavailability 177 4.2.4 Mode of action and selectivity 180 4.2.5 Bacterial resistance 181 4.2.6 Clinical applications 182 4.2.7 Adverse drug reactions 187 4.2.8 Drug interactions 189 4.2.9 Recent developments 191 References 193 4.3 Tetracycline antibiotics 197 Key points 197 4.3.1 Discovery 197 4.3.2 Synthesis 200 4.3.3 Bioavailability 205 4.3.4 Mode of action and selectivity 210 4.3.5 Bacterial resistance 213 4.3.6 Clinical applications 217 4.3.7 Adverse drug reactions 223 4.3.8 Drug interactions 224 4.3.9 Recent developments 224 References 225 4.4 Chloramphenicol 231 Key points 231 4.4.1 Discovery 231 4.4.2 Synthesis 231 4.4.3 Bioavailability 232 4.4.4 Mode of action and selectivity 235 4.4.5 Bacterial resistance 235 4.4.6 Clinical applications 236 4.4.7 Adverse drug reactions 239 4.4.8 Drug interactions 239 4.4.9 Recent developments 240 References 241 4.5 Oxazolidinones 243 Key points 243 4.5.1 Discovery 243 4.5.2 Synthesis 245 4.5.3 Bioavailability 247 4.5.4 Mode of action and selectivity 248 4.5.5 Bacterial resistance 249 4.5.6 Clinical applications 251 4.5.7 Adverse drug reactions 252 4.5.8 Drug interactions 253 4.5.9 Recent developments 254 References 254 Questions 259 SECTION 5 AGENTS TARGETING CELL-WALL SYNTHESIS 261 5.1 b-Lactam antibiotics 263 Key points 263 5.1.1 Discovery 263 5.1.2 Synthesis 272 5.1.3 Bioavailability 277 5.1.4 Mode of action and selectivity 284 5.1.5 Bacterial resistance 285 5.1.6 Clinical applications 290 5.1.7 Adverse drug reactions 296 5.1.8 Drug interactions 298 5.1.9 Recent developments 300 References 301 5.2 Glycopeptide antibiotics 305 Key points 305 5.2.1 Discovery 305 5.2.2 Synthesis 306 5.2.3 Bioavailability 307 5.2.4 Mode of action and selectivity 308 5.2.5 Bacterial resistance 309 5.2.6 Clinical applications 313 5.2.7 Adverse drug reactions 314 5.2.8 Drug interactions 316 5.2.9 Recent developments 316 References 317 5.3 Cycloserine 319 Key points 319 5.3.1 Discovery 319 5.3.2 Synthesis 320 5.3.3 Bioavailability 320 5.3.4 Mode of action and selectivity 321 5.3.5 Bacterial resistance 323 5.3.6 Clinical applications 323 5.3.7 Adverse drug reactions 325 5.3.8 Drug interactions 325 5.3.9 Recent developments 325 References 325 5.4 Isoniazid 327 Key points 327 5.4.1 Discovery 327 5.4.2 Synthesis 328 5.4.3 Bioavailability 329 5.4.4 Mode of action and selectivity 329 5.4.5 Bacterial resistance 330 5.4.6 Clinical applications 331 5.4.7 Adverse drug reactions 333 5.4.8 Drug interactions 334 5.4.9 Recent developments 335 References 335 5.5 Daptomycin 339 Key points 339 5.5.1 Discovery 339 5.5.2 Synthesis 340 5.5.3 Bioavailability 341 5.5.4 Mode of action and selectivity 341 5.5.5 Bacterial resistance 343 5.5.6 Clinical applications 343 5.5.7 Adverse drug reactions 344 5.5.8 Drug interactions 345 5.5.9 Recent developments 345 References 346 Questions 349 Index 351

Read more less

Book SynopsisPharmaceutical Emulsions: A Drug Developer's Toolbag covers all the key aspects of pharmaceutical emulsions, starting from the fundamental scientific basics, to the pharmaceutical forms and the chemical tests for its application.Table of ContentsMathematical symbols (with normal units) xi Acronyms and abbreviations xiii Preface xv Acknowledgements xvii About the companion website xix I Product considerations: medicinal formulations 1 1 Historical perspective 5 1.1 Landmarks 5 1.2 Significant discoveries 7 1.3 Difficulties 8 1.4 Traditional uses 10 1.5 Product regulation 13 2 What is an emulsion? 15 2.1 States of matter 24 2.2 Summary thermodynamics 34 2.3 Interfacial tension and wetting 36 2.4 Shear and size reduction 46 2.5 Raw materials 47 3 Stability, metastability and instability 49 3.1 Stokes’ law 51 3.2 Derjaguin–Landau–Verwey–Overbeek (DLVO) theory 52 3.3 Interfacial rheology 56 4 Manufacture 63 4.1 Premixing 63 4.2 High-shear mixers and size reduction 64 4.3 Multiple and microemulsions 65 4.4 Hot melt (steriles) 65 4.5 Filling 66 II Forms, uses and applications: biopharmaceutics 67 5 Creams and ointments 69 5.1 Nutraceuticals and cosmeceuticals 71 5.2 Medicinals 71 6 Pastes and bases 77 6.1 Emolliency 77 6.2 Suppositories 78 6.3 Pessaries 79 7 IV colloids 81 7.1 Needle free 86 7.2 Ocular therapy 87 7.3 Cancer 88 7.4 Antimicrobials 90 7.5 Temperature-sensitive matrices and release forms 93 7.6 Targeted endosomal use 94 7.7 Solid lipid nanoparticles 95 7.8 Diagnostic emulsions 98 8 Transdermal patches: semisolids 99 8.1 Hormones 104 8.2 Analgesia 104 8.3 Anaesthesia 104 8.4 Nicotine 105 8.5 Inserts: vaginal rings 105 9 Gels 107 9.1 Micro- and nanogels 107 9.2 Semisolids 107 10 Implants 109 10.1 Plastics and glasses 109 10.2 Thermoresponsive materials 110 11 De novo science, sustainable novel products and platform applications 111 11.1 Tablets 113 11.2 Metered-dose inhalers 113 11.3 Blood substitutes 114 III Tests: chemistry to control the quality, efficacy and fitness for purpose of a product 117 12 Physicochemical properties 119 12.1 Thermal evaluation (differential scanning calorimetry) and lipid polymorphs 124 12.2 Drug form, log P and Lipinski rules 129 12.3 Skin and epithelial models 133 12.4 Drug delivery routes 134 13 Sizing and microscopy 137 13.1 ζ -potential 137 13.2 Hydrodynamic diameter 139 14 Rheology, texture, consistency and spreadability 141 14.1 Bulk properties 141 14.2 Solid-state and nanorheological properties 144 14.3 Interfacial properties 144 15 Quality control, process analytical technology and accelerated testing 149 15.1 Preformulation, high-throughput screening 150 15.2 Industrial concerns 151 15.3 Rancimat and other methods 152 Questions 155 Guide for readers 155 Specimen 'test' questions 155 Answers 168 References 173 Index 181

Read more less

Book SynopsisChitosan is a linear polysaccharide commercially produced by the deacetylation of chitin. It is non-toxic, biodegradable, biocompatible, and acts as a bioadhesive with otherwise unstable biomolecules - making it a valuable component in the formulation of biopharmaceutical drugs. Chitosan-Based Systems for Biopharmaceuticals provides an extensive overview of the application of chitosan and its derivatives in the development and optimisation of biopharmaceuticals. The book is divided in four different parts. Part I discusses general aspects of chitosan and its derivatives, with particular emphasis on issues related to the development of biopharmaceutical chitosan-based systems. Part II deals with the use of chitosan and derivatives in the formulation and delivery of biopharmaceuticals, and focuses on the synergistic effects between chitosan and this particular subset of pharmaceuticals. Part III discusses specific applications of chitosan and its derivatives for biopharmaceutiTable of ContentsList of Contributors xvii Foreword xxiii Marıa Jose Alonso Preface xxv Acknowledgments xxvii Part One General Aspects of Chitosan 1 1 Chemical and Technological Advances in Chitins and Chitosans Useful for the Formulation of Biopharmaceuticals 3 Riccardo A. A. Muzzarelli 1.1 Introduction 3 1.2 Safety of Chitins and Chitosans 4 1.3 Ionic Liquids: New Solvents and Reaction Media 5 1.4 Chitin and Chitosan Nanofibrils 8 1.5 Electrospun Nanofibers 10 1.6 Polyelectrolyte Complexes and Mucoadhesion 12 1.7 Conclusions and Future Perspectives 16 2 Physical Properties of Chitosan and Derivatives in Sol and Gel States 23 Marguerite Rinaudo 2.1 Introduction 23 2.2 Chitin 24 2.3 Chitosan 28 2.4 Conclusions and Future Perspectives 36 3 Absorption Promotion Properties of Chitosan and Derivatives 45 Akira Yamamoto 3.1 Introduction 45 3.2 Effect of Chitosan on the Intestinal Absorption of Poorly Absorbable Drugs 47 3.3 Effect of Chitosan Derivatives on the Intestinal Absorption of Poorly Absorbable Drugs 47 3.4 Effect of Chitosan Oligomers on the Intestinal Absorption of Poorly Absorbable Drugs 48 3.5 Colon-Specific Delivery of Insulin Using Chitosan Capsules 51 3.6 Conclusions and Future Perspectives 54 4 Biocompatibility and Biodegradation of Chitosan and Derivatives 57 Ahmad Sukari Halim, Lim Chin Keong, Ismail Zainol, and Ahmad Hazri Abdul Rashid 4.1 Introduction 57 4.2 Biocompatibility Evaluation of Chitosan and Derivatives 58 4.3 Biodegradation of Chitosan and Derivatives 65 4.4 Conclusions and Future Perspectives 69 5 Biological and Pharmacological Activity of Chitosan and Derivatives 75 Teresa Cunha, Branca Teixeira, Barbara Santos, Marlene Almeida, Gustavo Dias, and Jose das Neves 5.1 Introduction 75 5.2 Biological Activity 76 5.3 Chitosan's Usefulness in Therapy and Alternative Medicine 82 5.4 Conclusions and Future Perspectives 84 6 Biological, Chemical, and Physical Compatibility of Chitosan and Biopharmaceuticals 93 Masayuki Ishihara, Masanori Fujita, Satoko Kishimoto, Hidemi Hattori, and Yasuhiro Kanatani 6.1 Introduction 93 6.2 Structural Features of Chitosan and Its Derivatives 94 6.3 Biocompatibility for Chitosan and Its Derivatives 95 6.4 Biocompatibility of Photo-Cross-Linkable Chitosan Hydrogel 98 6.5 Physical and Chemical Compatibility of Chitosan and Its Derivatives 100 6.6 Conclusions and Future Perspectives 102 7 Approaches for Functional Modification or Cross-Linking of Chitosan 107 A. Anitha, N. Sanoj Rejinold, Joel D. Bumgardner, Shanti V. Nair, and Rangasamy Jayakumar 7.1 Introduction 107 7.2 General Awareness of Chitosan Cross-Linking Methods 108 7.3 Modified Chitosan: Synthesis and Characterization 112 7.4 Applications of Modified Chitosan and Its Derivatives in Drug Delivery 118 7.5 Conclusions and Future Perspectives 118 Part Two Biopharmaceuticals Formulation and Delivery Aspects Using Chitosan and Derivatives 125 8 Use of Chitosan and Derivatives in Conventional Biopharmaceutical Dosage Forms Formulation 127 Teofilo Vasconcelos, Pedro Barrocas, and Rui Cerdeira 8.1 Introduction 127 8.2 Advantageous Properties of Chitosan and Its Derivatives 128 8.3 Oral Administration 129 8.4 Buccal Administration 131 8.5 Nasal Administration 132 8.6 Pulmonary Administration 132 8.7 Transdermal Administration 133 8.8 Conclusions and Future Perspectives 133 9 Manufacture Techniques of Chitosan-Based Microparticles and Nanoparticles for Biopharmaceuticals 137 Franca Ferrari, M. Cristina Bonferoni, Silvia Rossi, Giuseppina Sandri, and Carla M. Caramella 9.1 Introduction 137 9.2 Water-in-Oil Emulsion and Chemical Cross-linking 138 9.3 Drying Techniques 141 9.4 Ionic Cross-linking Methods 144 9.5 Coacervation and Precipitation Method 151 9.6 Direct Interaction between Chitosan and Biopharmaceuticals 152 9.7 Conclusions and Future Perspectives 153 10 Chitosan and Derivatives for Biopharmaceutical Use: Mucoadhesive Properties 159 Katharina Leithner and Andreas Bernkop-Schnurch 10.1 Introduction 159 10.2 Mucoadhesion 160 10.3 Chitosan and Its Derivatives 161 10.4 Biopharmaceutical Use of Chitosan and Its Derivatives 171 10.5 Conclusions and Future Perspectives 175 11 Chitosan-Based Systems for Mucosal Delivery of Biopharmaceuticals 181 Sonia Al-Qadi, Ana Grenha, and Carmen Remunan-Lopez 11.1 Introduction 181 11.2 Important Challenges for the Delivery of Biopharmaceuticals by Mucosal Routes 182 11.3 Interest in Chitosan for Mucosal Delivery of Biopharmaceuticals 184 11.4 Chitosan-Based Delivery Nanosystems for Mucosal Delivery of Biopharmaceuticals 188 11.5 Conclusions and Future Perspectives 200 12 Chitosan-Based Delivery Systems for Mucosal Vaccination 211 Gerrit Borchard, Farnaz Esmaeili, and Simon Heuking 12.1 Introduction 211 12.2 Adjuvant Properties of Chitosan 212 12.3 Chitosan in the Delivery of Protein and Subunit Vaccines 213 12.4 Chitosan-Based Formulations of DNAVaccines 215 12.5 Vaccine Formulations Using Chitosan in Combination with Other Polymers 216 12.6 Chitosan Derivatives in Vaccine Carrier Design 217 12.7 Conclusions and Future Perspectives 220 13 Chitosan-Based Nanoparticulates for Oral Delivery of Biopharmaceuticals 225 Filipa Antunes, Fernanda Andrade, and Bruno Sarmento 13.1 Introduction 225 13.2 Challenges on the Oral Delivery of Therapeutic Proteins 226 13.3 Challenges on the Oral Delivery of Genetic Material 227 13.4 Role of Chitosan in the Protection of Biopharmaceuticals in the Gastrointestinal Tract 229 13.5 Chitosan-Based Nanoparticles for Oral Delivery of Therapeutic Proteins 232 13.6 Chitosan-Based Nanoparticles for Oral Delivery of Genetic Material 234 13.7 Conclusions and Future Perspectives 236 14 Chitosan-Based Systems for Ocular Delivery of Biopharmaceuticals 243 Suresh P. Vyas, Rishi Paliwal, and Shivani Rai Paliwal 14.1 Introduction 243 14.2 Ocular Delivery of Biopharmaceuticals 244 14.3 Chitosan: A Suitable Biomaterial for Ocular Therapeutics 244 14.4 Chitosan-Based Systems for Ocular Delivery of Biomacromolecules 245 14.5 Toxicological and Compatibility Aspects of Chitosan-Based Ocular Systems 249 14.6 Conclusions and Future Perspectives 250 15 Chemical Modification of Chitosan for Delivery of DNA and siRNA 255 You-Kyoung Kim, Hu-Lin Jiang, Ding-Ding Guo, Yun-Jaie Choi, Myung-Haing Cho, Toshihiro Akaike, and Chong-Su Cho 15.1 Introduction 255 15.2 Hydrophilic Modification 256 15.3 Hydrophobic Modification 257 15.4 Specific Ligand Modification 259 15.5 pH-Sensitive Modification 264 15.6 Conclusions and Future Perspectives 269 Part Three Advanced Application of Chitosan and Derivatives for Biopharmaceuticals 275 16 Target-Specific Chitosan-Based Nanoparticle Systems for Nucleic Acid Delivery 277 Shardool Jain and Mansoor Amiji 16.1 Introduction 277 16.2 Chitosan-Based Nanoparticle Delivery Systems 283 16.3 Illustrative Examples of DNAVaccine Delivery 286 16.4 Illustrative Examples of Nucleic Acid Delivery Systems for Cancer Therapy 288 16.5 Illustrative Examples of Nucleic Acid Delivery Systems for Anti-Inflammatory Therapy 291 16.6 Conclusions and Future Perspectives 294 17 Functional PEGylated Chitosan Systems for Biopharmaceuticals 301 Hee-Jeong Cho, Goen Kim, Hyeok-Seung Kwon, and Yu-Kyoung Oh 17.1 Introduction 301 17.2 PEGylated Chitosan for the Delivery of Proteins and Peptides 304 17.3 PEGylated Chitosan for Delivery of Nucleic Acids 308 17.4 PEGylated Chitosan for Delivery of Other Macromolecular Biopharmaceuticals 311 17.5 PEGylated Chitosan Used for Cellular Scaffolds 313 17.6 Conclusions and Future Perspectives 313 18 Stimuli-Sensitive Chitosan-Based Systems for Biopharmaceuticals 319 Cuiping Zhai, Jinfang Yuan, and Qingyu Gao 18.1 Introduction 319 18.2 pH-Sensitive Chitosan-Based Systems 319 18.3 Thermosensitive Chitosan-Based Systems 321 18.4 pH-Sensitive and Thermosensitive Chitosan-Based Systems 323 18.5 pH- and Ionic-Sensitive Chitosan-Based Systems 325 18.6 Photo-Sensitive Chitosan-Based Systems 325 18.7 Electrical-Sensitive Chitosan-Based Systems 326 18.8 Magnetic-Sensitive Chitosan-Based Systems 326 18.9 Chemical Substance-Sensitive Chitosan-Based Systems 327 18.10 Conclusions and Future Perspectives 327 19 Chitosan Copolymers for Biopharmaceuticals 333 Ramon Novoa-Carballal, Ricardo Riguera, and Eduardo Fernandez-Megia 19.1 Introduction 333 19.2 Chitosan-g-Poly(Ethylene Glycol) 337 19.3 Chitosan-g-Polyethylenimine 347 19.4 Other Copolymers of Chitosan 357 19.5 Copolymers of Chitosan with Promising Applications 363 19.6 Conclusions and Future Perspectives 368 20 Application of Chitosan for Anticancer Biopharmaceutical Delivery 381 Claudia Philippi, Brigitta Loretz, Ulrich F. Schaefer, and Claus-Michael Lehr 20.1 Introduction 381 20.2 Chitosan and Cancer: Intrinsic Antitumor Activity of the Polymer Itself 382 20.3 Chitosan Formulations Developed for Classic Anticancer Drugs 383 20.4 Biopharmaceuticals Delivered by Chitosan Preparations 384 20.5 Active Targeting Strategies and Multifunctional Chitosan Formulations 388 20.6 Conclusions and Future Perspectives 389 21 Chitosan-Based Biopharmaceutical Scaffolds in Tissue Engineering and Regenerative Medicine 393 Tao Jiang, Meng Deng, Wafa I. Abdel- Fattah, and Cato T. Laurencin 21.1 Introduction 393 21.2 Fabrication of Chitosan-Based Biopharmaceuticals Scaffolds 395 21.3 Applications of Chitosan-Based Biopharmaceutical Scaffolds in Tissue Engineering and Regenerative Medicine 403 21.4 Future Trends: Regenerative Engineering 416 21.5 Conclusions and Future Perspectives 417 22 Wound-Healing Properties of Chitosan and Its Use in Wound Dressing Biopharmaceuticals 429 Tyler G. St. Denis, Tianhong Dai, Ying-Ying Huang, and Michael R. Hamblin 22.1 Introduction 429 22.2 Brief Review of Wound Repair 430 22.3 Wound-Healing Effects of Chitosan 433 22.4 Chitosan for Wound Therapeutics Delivery 440 22.5 Conclusions and Future Perspectives 444 Part Four Regulatory Status, Toxicological Issues, and Clinical Perspectives 451 23 Toxicological Properties of Chitosan and Derivatives for Biopharmaceutical Applications 453 Thomas J. Kean and Maya Thanou 23.1 Introduction 453 23.2 In Vitro Toxicity of Chitosan and Derivatives 454 23.3 In Vivo Toxicity of Chitosan and Derivatives 457 23.4 Conclusions and Future Perspectives 459 24 Regulatory Status of Chitosan and Derivatives 463 Michael Dornish, David S. Kaplan, and Sambasiva R. Arepalli 24.1 Introduction 463 24.2 Source 464 24.3 Characterization 464 24.4 Purity 465 24.5 Applications of Advanced Uses of Chitosan 466 24.6 Regulatory Considerations for Chitosan and Chitosan Derivatives in the European Union, and Medical Devices or Combination Products with Medical Device (CDRH) Lead 468 24.7 Regulatory Pathways 469 24.8 Chitosan Medical Products: US Regulatory Review Processes for Medical Devices or Combination Products with CDRH Lead 469 24.9 Chitosan Wound Dressings 470 24.10 The European Regulatory System: The European Medicines Agency (EMA) and European Directorate for the Quality of Medicines (EDQM) 474 24.11 Further Regulatory Considerations 475 24.12 Conclusions and Future Perspectives 477 24.13 Disclaimer 478 25 Patentability and Intellectual Property Issues Related to Chitosan-Based Biopharmaceutical Products 483 Mafalda Videira and Rogerio Gaspar 25.1 Introduction 483 25.2 Setting the Scene: The Role of Chitosan as a Pharmaceutical Excipient 484 25.3 Addressing the Drivers for Scientific Progress on Chitosan: Innovation and Inventability 495 25.4 Conclusions and Future Perspectives 496 26 Quality Control and Good Manufacturing Practice (GMP) for Chitosan-Based Biopharmaceutical Products 503 Torsten Richter, Maika Gulich, and Katja Richter 26.1 Introduction 504 26.2 Regulatory Requirements for Production 505 26.3 Manufacturing GMP: Fundamental Considerations 508 26.4 Requirements for Rooms, Personnel, and Equipment 511 26.5 Qualification and Validation 511 26.6 Quality Control 513 26.7 Monitoring and Maintenance of a GMP System 519 26.8 Conclusions and Future Perspectives 522 27 Preclinical and Clinical Use of Chitosan and Derivatives for Biopharmaceuticals: From Preclinical Research to the Bedside 525 David A. Zaharoff, Michael Heffernan, Jonathan Fallon, and John W. Greiner 27.1 Introduction 525 27.2 Chitosan as a Parenteral (Subcutaneous) Vaccine Platform 526 27.3 Chitosan as an Immunotherapeutic Platform 530 27.4 Conclusions and Future Perspectives 537 References 539 Index 543

Read more less

Book SynopsisThis comprehensive volume provides an homogeneous coverage of the whole area of solid-phase synthesis/combinatorial technology and clarifies the strategies used to plan, design, prepare and test combinatorial libraries.Trade Review"For both experienced combinatorial chemists and newcomers ...Seneci...provides an overview of recent developments in the realm where chemistry intersects with automation, statistics, information science, and certain biological disciplines." (SciTech Book News, Vol. 25, No. 2, June 2001) "...[a] comprehensive review of the whole combinatorial area" (Chemistry in Britain, January 2001) "...a welcome addition to the rapidly developing field of combinatorial synthetic chemistry..." (Pharmaceutical Research, Vol. 18, No. 9, September 2001)Table of ContentsSolid-Phase Synthesis: Basic Principles. Solid-Phase Synthesis: Oligomeric Molecules. Solid-Phase Synthesis: Small Organic Molecules. Combinatorial Technologies: Basic Principles. Synthetic Organic Libraries: Library Design and Properties. Synthetic Organic Libraries: Solid-Phase Discrete Libraries. Synthetic Organic Libraries: Solid-Phase Pool Libraries. Synthetic Organic Libraries: Solution-Phase Libraries. Applications of Synthetic Libraries. Biosynthetic Combinatorial Libraries. Materials and Polymeric Combinatorial Libraries. Index.

Read more less

Book SynopsisProvides an authoritative source of practical information on stereochemistry and its impact on drug development. Unlike other books which focus on synthesis, this work explores analytical, pharmacological, and regulatory topics in dealing with the theory and practice of stereochemistry in the pharmaceutical industry today. It specifically addresses how the body metabolizes chiral molecules; the varying effects of different chiral molecules; and provides detailed evaluations of current seperation techniques. Includes regulatory information.Table of ContentsPartial table of contents: Chirality and Drug Hazards (H. Aboul-Enein & L. Basha). Stereochemical Aspects of Drug Metabolism (J. Mason & A. Hutt). Some Examples for Stereoselective Biotransformation of Drugs (G. Blaschke). Chiral Barbiturates: Synthesis, Chromatographic Resolutions, and Biological Activity (J. Bojarski). Stereogenic Elements of Pharmaceutical Compounds: Some Aspects on Isomerism, Resolution, and Stereochemical Integrity (S. Allenmark). The Importance of Chiral Separations in Pharmaceuticals (S. Ahuja). Micelle-Mediated Capillary Electrophoretic Separation of Enantiomeric Compounds (M. Swartz & P. Brown). Chiral Derivatization Reagents in the Bioanalysis of Optically Active Drugs with Chromophore-Based Detection (R. Büschges, et al.). Circular Dichroism in the Study of Stereoselective Binding of Drugs to Serum Proteins (C. Bertucci, et al.).

Read more less

Book SynopsisDiscusses the significance of clinical trials in the context of 21st century health care, with contributions on issues such as: The role of experiments in health care; Keeping track of trial reports; and, The nuts and bolts of doing trials. It is intended for trialists and researchers conducting efficient, high quality, and relevant studies.Table of ContentsContributors. Foreword. Preface. Acknowledgements. Comparing like with like and the development of randomisation. Why we need randomised controlled trials. Keeping track of trial reports; the experience of The Cochrane Trials Register. What have we learned from 50 years of randomised trials for people with schizophrenia. Big is still beautiful: why we still need large simple trials. Factors that limit the number, quality and progress of randomised trials. The nuts and bolts of doing trials. Building resources for randomised trials. The role of data monitoring committees. Bayesian perspectives on the ethics of trials. "Empowering" patient choice about participation in trials?. Index

Read more less

Book SynopsisSuitable for a stand-alone pharmacy lab course or for the lab portion of a pharmacy practice course, Pharmacy Labs for Technicians teaches students detailed lab procedures and skills using hands-on practice. Students learn both administrative and clinical procedures, such as filling prescriptions, compounding medications, and preparing sterile intravenous products.

Read more less

Book SynopsisProvides comprehensive coverage of pharmacy technician practice, along with coverage of business operations in a community pharmacy, professionalism and ethics in the workplace, and pharmacy careers. This text also offers insight on pharmacology, e-prescribing, pharmacy automation systems, medication safety initiatives, innovative drug delivery systems, and medication therapy management services.

Read more less

Book SynopsisExamining the Circulation, Commodification, and Organization of Healing Goods and Healing Knowledge

Read more less

Book SynopsisThis comprehensive volume provides the reader valuable insight into the major areas of biomedical nanomaterials, advanced nanomedicine, nanotheragnostics, and cutting-edge nanoscaffolds. The ability to control the structure of materials allows scientists to accomplish what once appeared impossible before the advent of nanotechnology. It is now possible to generate nanoscopic self-assembled and self-destructive robots for effective utilization in therapeutics, diagnostics, and biomedical implants. Nanoscopic therapeutic systems incorporate therapeutic agents, molecular targeting, and diagnostic imaging capabilities and they have emerged as the next generation of multifarious nanomedicine to improve the therapeutic outcome including chemo and translational therapy. Nanomaterials in Drug Delivery, Imaging, and Tissue Engineering comprises fifteen chapters authored by senior scientists, and is one of the first books to cover nanotheragnostics, which is the neTrade Review“The volume was written by many scientists working in the new area of nanotechnology. Each chapter has an extensive reference list and there is a short index at the end.” (Optics & Photonics News, 22 November 2013)Table of ContentsPreface xv Part I: Biomedical nanomaterials 1 Nanoemulsions: Preparation, Stability and Application in Biosciences 1 Thomas Delmas, Nicolas Atrux-Tallau, Mathieu Goutayer, SangHoon Han, Jin Woong Kim, and Jérôme Bibette 1.1 Introduction 2 1.2 Nanoemulsion:A Thermodynamic Definition and Its Practical Implications 5 1.2.1 Generalities on Emulsions 5 1.2.2 Nanoemulsion vs. Microemulsion, a Thermodynamic Definition 6 1.3 Stable Nanoemulsion Formulation 9 1.3.1 Nanoemulsion Production 9 1.3.2 Nanoemulsion Stability Rules 11 1.3.3 Nanoemulsion Formulation Domain 16 1.3.4 Conclusion on the Formulation of Stable Nanoemulsions 21 1.4 Nanoencapsulation in Lipid Nanoparticles 21 1.4.1 Aim ofActive Encapsulation 21 1.4.2 Lipid Complexity and Influence of Their Physical State 23 1.4.3 Amorphous Lipids for a Large Range of Encapsulated Molecules 27 1.4.4 Lipids Viscosity and Release 31 1.4.5 Conclusion on the Use ofAmorphous Lipid Matrices for Control OverActive Encapsulation and Release 34 1.5 Interactions between Nanoemulsions and the Biological Medium: Applications in Biosciences 35 1.5.1 Nanoemulsion Biocompatibility 35 1.5.2 Classical TargetingApproach by Chemical Grafting – Example of Tumor Cell Targeting by Crgd Peptide for Cancer Diagnosis and Therapy 38 1.5.3 New ‘No Synthesis Chemistry’Approach – Example of Pal-KTTKS andAsiaticoside Targeting for CosmeticActives Delivery 41 1.5.4 Conclusion on Nanoemulsions Application in Biosciences 46 1.6 General Conclusion 47 References 48 2 Multifunctional Polymeric Nanostructures for Therapy and Diagnosis 57 Angel Contreras-García and Emilio Bucio 2.1 Introduction 58 2.2 Polymeric-based Core-shell Colloid 61 2.3 Proteins and Peptides 64 2.4 Drug Conjugates and Complexes with Synthetic Polymers 65 2.5 Dendrimers, Vesicles, and Micelles 67 2.5.1 Dendrimers 67 2.5.2 Vesicles 68 2.5.3 Micelles 70 2.6 Smart Nanopolymers 71 2.6.1 Temperature and pH Stimuli-responsive Nanopolymers 72 2.6.2 Hydrogels 72 2.6.3 Stimuli Responsive Biomaterials 73 2.6.4 Interpenetrating Polymer Networks 74 2.7 Stimuli Responsive Polymer-metal Nanocomposites 75 2.8 Enzyme-responsive Nanoparticles 78 Acknowledgements 83 References 83 3 Carbon Nanotubes: Nanotoxicity Testing and Bioapplications 97 R. Sharma and S. Kwon 3.1 Introduction 98 3.1.1 What is Nanotoxicity of Nanomaterials? 98 3.2 Historical Review of Carbon Nanotube 99 3.3 Carbon Nanotubes (CNTs) and Other Carbon Nanomaterials 100 3.3.1 Physical Principles of Carbon Nanotube Surface Science 102 3.4 Motivation – Combining Nanotechnology and Surface Science with Growing Bioapplications 104 3.5 Cytotoxicity Measurement and Mechanisms of CNT Toxicity 111 3.1.6 In Vivo Studies on CNT Toxicity 113 3.1.7 Inflammatory Mechanism of CNT Cytoxicity 114 3.1.8 Characterization and Toxicity of SWCNT and MWCNT Carbon Nanotubes 116 3.6 MSCs Differentiation and Proliferation on Different Types of Scaffolds 120 3.6.1 An In Vivo Model CNT-Induced Inflammatory Response in Alveolar Co-culture System 122 3.6.2 Static Model: 3-Dimensional Tissue Engineered Lung 124 3.6.3 Dynamic Model: Integration of 3D Engineered Tissues into Cyclic Mechanical Strain Device 126 3.6.4 In Vivo MR Microimaging Technique of Rat Skin Exposed to CNT 127 3.7 New Lessons on CNT Nanocomposites 130 3.8 Conclusions 135 Part II: Advanced nanomedicine 4 Discrete Metalla-Assemblies as Drug Delivery Vectors 149 Bruno Therrien 4.1 Introduction 149 4.2 Complex-in-a-Complex Systems 150 4.3 Encapsulation of Pyrenyl-functionalized Derivatives 155 4.4 Exploiting the Enhanced Permeability and Retention Effect 159 4.5 Incorporation of Photosensitizers in Metalla-assemblies 162 4.6 Conclusion 165 Acknowledgments 165 References 166 5 Nanomaterials for Management of Lung Disorders and Drug Delivery 169 Jyothi U. Menon, Aniket S. Wadajkar, Zhiwe iXie, and Kytai T. Nguyen 5.1 Lung Structure and Physiology 170 5.2 Common Lung DiseasesAnd Treatment Methods 171 5.2.1 Lung Cancer 171 5.2.2 PulmonaryArterial Hypertension 172 5.2.3 Obstructive Lung Diseases 173 5.3 Types of Nanoparticles (NPs) 173 5.3.1 Liposomes 174 5.3.2 Micelles 176 5.3.3 Dendrimers 177 5.3.4 Polymeric Micro/Nanoparticles 177 5.4 Methods for Pulmonary Delivery 179 5.4.1 Nebulization 179 5.4.2 Metered Dose Inhalation (MDI) 182 5.4.3 Dry Powder Inhalation (DPI) 183 5.4.4 IntratrachealAdministration 183 5.5 Targeting Mechanisms 184 5.5.1 Passive Targeting 184 5.5.2 Active Targeting 185 5.5.3 Cellular Uptake Mechanisms 188 5.6 TherapeuticAgents Used for Delivery 188 5.6.1 ChemotherapeuticAgents 188 5.6.2 Bioactive Molecules 190 5.6.3 Combinational Therapy 190 5.7 Applications 191 5.7.1 Imaging/DiagnosticApplications 191 5.7.2 TherapeuticApplications 193 5.7.3 Lung Remodeling and Regeneration 194 5.8 Design Considerations of NPs 195 5.8.1 Half-life of NPs 195 5.8.2 Drug Release Mechanisms 195 5.8.3 Clearance Mechanisms in the Lung 196 5.9 Current Challenges and Future Outlook 197 6 Nano-Sized Calcium Phosphate (CaP) Carriers for Non-Viral Gene/Drug Delivery 199 Donghyun Lee, Geunseon Ahn and Prashant N. Kumta 6.1 Introduction 200 6.2 Vectors for Gene Delivery 202 6.2.1 Viral Vectors 203 6.2.2 Non-viral Vectors 203 6.2.3 Calcium Phosphate Vectors 205 6.3 Modulation of Protection and Release Characteristics of Calcium Phosphate Vector 213 6.4 Calcium Phosphate Carriers for Drug Delivery Systems 219 6.4.1 Antibiotics Delivery 219 6.4.2 Growth Factor Delivery 221 6.5 Variants of Nano-calcium Phosphates: Future Trends of the CaPDelivery Systems 221 Acknowledgements 223 References 223 7 Organics ModifiedMesoporous Silica for Controlled Drug Delivery Systems 233 Jingke Fu, Yang Zhao, Yingchun Zhu and Fang Chen 7.1 Introduction 233 7.2 Controlled Drug Delivery Systems Based on Organics Modified 7.2.1 MSNs-based Drug Delivery Systems Controlled by Physical Stimuli 238 7.2.2 MSNs-based Drug Delivery Systems Controlled by Chemical Stimuli 246 7.3 Conclusions 258 References 259 Part III: Nanotheragnostics 8 Responsive Polymer-Inorganic Hybrid Nanogels for Optical Sensing, Imaging, and Drug Delivery 263 Weitai Wu and Shuiqin Zhou 8.1 Introduction 264 8.2 Mechanisms of Response 268 8.2.1 Reception of an External Signal 268 8.2.2 Volume Phase Transition of the Hybrid Nanogels 275 8.2.4 Regulated Drug Delivery 282 8.3 Synthesis of Responsive Polymer-inorganic Hybrid Nanogels 285 8.3.1 Synthesis of the Hybrid Nanogels from Pre-synthesized Polymer Nanogels 285 8.3.2 Synthesis of the Hybrid Nanogels from Pre-synthesized Inorganic NPs 289 8.3.3 Synthesis of the Hybrid Nanogels by a Heterogeneous Polymerization Method 292 8.4 Applications 293 8.4.1 Responsive Polymer-inorganic Hybrid Nanogels in Optical Sensing 293 8.4.2 Responsive Polymer-inorganic Hybrid Nanogels in Diagnostic Imaging 299 8.4.3 Responsive Polymer-inorganic Hybrid Nanogels in Drug Delivery 301 References 306 9 Core/Shell Nanoparticles for Drug Delivery and Diagnosis 315 Hwanbum Lee, Jae Yeon Kim, Eun Hee Lee, Young In Park, Keun Sang Oh, Kwangmeyung Kim, Ick Chan Kwonand Soon Hong Yuk 9.2 Core/Shell NPs from Polymeric Micelles 319 9.2.1 Polymeric Micelles with Physical Drug Entrapment 319 9.2.2 Polymeric Micelles with Drug Conjugation 321 9.2.3 Polymeric Micelles Formed by Temperature-Induced Phase Transition 323 9.3 Phospholipid-based Core/Shell Nanoparticles 325 9.4 Layer-by-Layer-Assembled Core/Shell Nanoparticles 329 9.5 Core/Shell NPs for Diagnosis 330 9.4 Conclusions 331 Acknowledgments 331 References 331 10 Dendrimer Nanoparticles and Their Applications in Biomedicine 339 Arghya Paul, Wei Shao, Tom J. Burdon, Dominique Shum-Tim and Satya Prakash 10.1 Introduction 340 10.2 Dendrimers and Their Characteristics 341 10.3 Biomolecular Interactions of Dendrimer Nanocomplexes 343 10.3.1 Genes (siRNA/ANS/DNA) 344 10.3.2 Drugs and Pharmaceutics 345 10.4 PotentialApplications of Dendrimer in Nanomedicine 347 10.4.1 Delivery of Chemotherapeutics 347 10.4.2 Delivery of Biomolecules 348 10.4.3 Imaging 350 10.5 Conclusion 353 Acknowledgements 355 Indexing words 355 References 355 11 Theranostic Nanoparticles for Cancer Imaging and Therapy 363 Mami Murakami, Mark J. Ernsting and Shyh-Dar Li 11.1 Introduction 363 11.2 Multifunctional Nanoparticles for Noninvasive 11.2.1 Radiolabeled Nanoparticles 366 11.2.2 Fluorescence Imaging of Biodistribution 367 11.2.3 Multimodal Radiolabel and Fluorescence Imaging of Biodistribution 368 11.2.4 MRI Imaging of Biodistribution 369 11.2.5 Multimodal MRI and Fluorescence Imaging of Biodistribution 371 11.2.6 Multimodal Optical and CT Imaging of Biodistribution 372 11.2.7 Pharmacokinetics and Pharmacodynamics of Theranostics vs Diagnostics 373 11.3 Multifunctional Nanoparticles for Monitoring Drug Release 375 11.3.1 MRI imaging of Drug Release 375 11.3.2 Fluorescent Imaging of Drug Release 379 11.4 Theranostics to Image Therapeutic Response 380 11.5 Conclusion and Future Directions 382 Acknowledgement 383 References 383 Part IV: Nanoscaffolds technology 12 Nanostructure Polymers in Function Generating Substitute and Organ Transplants 389 S.K. Shukla 12.1 Introduction 389 12.2 Important Nanopolymers 391 12.2.1 Hydrogels 393 12.2.2 Bioceramics 394 12.2.3 Bioelastomers 395 12.2.4 Chitosan and Derivatives 396 12.2.5 Gelatine 396 12.3 MedicalApplications 397 12.3.1 Tissue Engineering for Function Generating 398 12.3.2 Tissue Engineering inArtificial Heart 400 12.3.3 Tissue Engineering in Nervous System 401 12.3.4 Bone Transplants 404 12.3.5 Kidney and Membrane Transplants 406 12.3.6 Miscellaneous 409 Acknowledgement 411 References 411 13 Electrospun Nanofiberfor Three Dimensional Cell Culture 417 Yashpal Sharma, Ashutosh Tiwari and Hisatoshi Kobayashi 13.1 Introduction 417 13.2 Nanofiber Scaffolds Fabrication Techniques 419 13.2.1 Self-Assembly 419 13.2.2 Phase Separation 421 13.2.3 Electrospinning 422 13.3 Parameters of Electrospinning Process 424 13.3.1 Viscosity or Concentration of the Polymeric Solution 424 13.3.2 Conductivity and the Charge Density 425 13.3.3 Molecular Weight of Polymer 425 13.3.4 Flow Rate 425 13.3.5 Distance from Tip to Collector 425 13.3.6 VoltageApplied 426 13.3.7 Environmental Factors 426 13.4 Electrospun Nanofibers for Three-dimensional Cell Culture 426 13.5 Conclusions 429 References 431 14 Magnetic Nanoparticles in Tissue Regeneration 435 Anuj Tripathi, Jose Savio Melo and Stanislaus Francis D’Souza 14.1 Introduction 435 14.2 Magnetic Nanoparticles: Physical Properties 438 14.3 Synthesis of Magnetic Nanoparticles 440 14.4 Design and Structure of Magnetic Nanoparticles 443 14.5 Stability and Functionalization of Magnetic Nanoparticles 445 14.6 Cellular Toxicity of Magnetic Nanoparticles 450 14.7 Tissue EngineeringApplications of Magnetic Nanoparticles 453 14.7.1 Magnetofection 455 14.7.2 Cell-patterning 458 14.7.3 Magnetic Force-induced Tissue Fabrication 461 14.8 Challenges and Future Prospects 473 Acknowledgement 474 References 474 15 Core-sheath Fibersfor Regenerative Medicine 485 Rajesh Vasita and Fabrizio Gelain 15.1 Introduction 486 15.1.1 Tissue Engineering 487 15.1.2 Scaffold Fabrication Technology 488 15.2 Core-sheath Nanofiber Technology 489 15.2.1 Co-axial Electrospinning 491 15.2.2 Emulsion Electrospinning 501 15.2.3 Melt Co-axial Electrospinning 503 15.3Application of Core-sheath Nanofibers 504 15.3.1 Delivery of Bioactive Molecules 504 15.3.2 Tissue Engineering 513 15.4 Conclusions 519 References 519

Read more less

Book SynopsisThe Pharmaceutical Studies Reader is an engaging survey of the field that brings together provocative, multi-disciplinary scholarship examining the interplay of medical science, clinical practice, consumerism, and the healthcare marketplace.Table of ContentsAcknowledgements vii 1 Introduction 1Jeremy A. Greene and Sergio Sismondo Part I Pharmaceutical Lives 17 2 The Pharmaceuticalisation of Society? A Framework for Analysis 19Simon J. Williams, Paul Martin and Jonathan Gabe 3 Pharmaceutical Witnessing: Drugs for Life in an Era of Direct]to]Consumer Advertising 33Joseph Dumit Part II New Drugs, Diseases, and Identities 49 4 Releasing the Flood Waters: Diuril and the Reshaping of Hypertension 51Jeremy A. Greene 5 Dep®ession and ConsumŠtion: Psychopharmaceuticals, Branding, and New Identity Practices 70Nathan Greenslit 6 BiDil: Medicating the Intersection of Race and Heart Failure 87Anne Pollock 7 Manufacturing Desire: The Commodification of Female Sexual Dysfunction 106Jennifer R. Fishman Part III Drugs and the Circulation of Medical Knowledge 121 8 Following the Script: How Drug Reps Make Friends and Influence Doctors 123Adriane Fugh]Berman and Shahram Ahari 9 Getting to Yes: Corporate Power and the Creation of a Psychopharmaceutical Blockbuster 133Kalman Applbaum 10 Pushing Knowledge in the Drug Industry: Ghost]Managed Science 150Sergio Sismondo 11 Transcultural Medicine: A Multi]Sited Ethnography on the Scientific]Industrial Networking of Korean Medicine 165Jongyoung Kim Part IV Political and Moral Economies of Pharmaceutical Research 179 12 Uncommon Trajectories: Steroid Hormones, Mexican Peasants, and the Search for a Wild Yam 181Gabriela Soto Laveaga 13 “Ready]to]Recruit” or “Ready]to]Consent” Populations? Informed Consent and the Limits of Subject Autonomy 195Jill A. Fisher 14 Clinical Trials Offshored: On Private Sector Science and Public Health 208Adriana Petryna 15 The Experimental Machinery of Global Clinical Trials: Case Studies from India 222Kaushik Sunder Rajan Part V Intellectual Property in Local and Global Markets 235 16 Intellectual Property and Public Health: Copying of HIV/AIDS Drugs by Brazilian Public and Private Pharmaceutical Laboratories 237Maurice Cassier and Marilena Correa 17 Global Pharmaceutical Markets and Corporate Citizenship: The Case of Novartis’ Anti]Cancer Drug Glivec 247Stefan Ecks 18 Generic Medicines and the Question of the Similar 261Cori Hayden Index 268

Read more less

Book SynopsisProvides solutions for two- and three-dimensional linear models of controlled-release systems Real-world applications are taken from used to help illustrate the methods in Cartesian, cylindrical and spherical coordinate systems Covers the modeling of drug-delivery systems and provides mathematical tools to evaluate and build controlled-release devices Includes classical and analytical techniques to solve boundary-value problems involving two- and three-dimensional partial differential equations Provides detailed examples, case studies and step-by-step analytical solutions to relevant problems using popular computational software Table of ContentsPreface ix Acknowledgements xi 1 Steady-State Analysis of a Two-Dimensional Model for Percutaneous Drug Transport 1 1.1 Separation of Variables in 2-D Cartesian Coordinates1 1.2 Model for Drug Transport across the Skin 3 1.3 Analytical Solution of the Diffusion Model in 2-D Cartesian Systems 4 1.4 Summary 6 1.5 Appendix: Maple, Mathematica, and Maxima Code Listings 6 Problems 10 References 12 2 Constant Drug Release from a Hollow Cylinder of Finite Length in Two Dimensions 13 2.1 Separation of Variables in 2-D Cylindrical Coordinates 13 2.2 Model for Drug Release from a Hollow Cylinder 15 2.3 Analytical Solution of the Transport Model in 2-D Cylindrical Coordinates 15 2.4 Summary 19 2.5 Appendix: Maple Code Listings 19 Problems 20 References 20 3 Analysis of Steady-State Growth Factor Transport Through Double-Layered Scaffolds 23 3.1 Governing Steady-State Transport Equations 23 3.2 Solution Procedure for Transport Through a Two-Layered Scaffold 25 3.3 Concentration Profile of Vascular Endothelial Growth Factor in Two Layers 31 3.4 Summary 32 3.5 Appendix: Maple Code Listings 33 Problems 37 References 38 4 Steady-State Two-Dimensional Diffusion in a Hollow Sphere 39 4.1 Separation of Variables and Legendre Polynomials in 2-D Spherical Coordinates 39 4.2 Model For 2-D Diffusion in a Sphere 43 4.3 Analytical Solution of 2-D Diffusion in Spherical Coordinates 46 4.4 Summary 49 4.5 Appendix: Maple, Mathematica, and Maxima Code Listings 49 Problems 56 References 57 5 Steady-State Three-Dimensional Drug Diffusion through Membranes from Distributed Sources 59 5.1 Separation of Variables in 3-D Cartesian Coordinates 59 5.2 Transport across the Membrane 61 5.3 Analytical Solution of the Diffusion Model in 3-D Cartesian Systems 63 5.4 Summary 68 5.5 Appendix: Maple Code Listings 69 Problems 73 References 73 6 Constant Drug Release from a Hollow Cylinder of Finite Length in Three Dimensions 75 6.1 Separation of Variables in 3-D Cylindrical Coordinates 75 6.2 Model For 3-D Drug Release from a Hollow Cylinder 77 6.3 Analytical Solution of the Transport Model in 3-D Cylindrical Coordinates 78 6.4 Summary 84 6.5 Appendix: Maple Code Listings 85 Problems 87 References 87 7 Sustained Drug Release from a Hollow Sphere in Three Dimensions 89 7.1 Method of Green’s Function in 3-D Spherical Coordinates 89 7.2 Model for Molecular Transport across the Wall of a Hollow Sphere 95 7.3 Analytical Solution of the Transport Model in 3-D Spherical Coordinates 96 7.4 Summary 97 7.5 Appendix: Maple, Mathematica and Maxima Code Listings 98 Problems 105 References 105 8 Analysis of Transient Growth Factor Transport Through Double-Layered Scaffolds 107 8.1 Laplace and Fourier-Bessel-based Methods in 2-D Cylindrical Coordinates 107 8.2 Governing Equations for Transport through Double-Layered Scaffolds 112 8.3 Concentration Profile of Vascular Endothelial Growth Factor in Two Layers 114 8.4 Summary 119 8.5 Appendix: Maple Code Listings 120 Problems 126 References 126 9 Molecular Diffusion through the Stomach Lining and into the Bloodstream 129 9.1 Laplace Transforms, Legendre Functions and Spherical Harmonics129 9.2 Spherical Diffusion in Three Dimensions 132 9.3 Analytical Solution of the Transient Transport Model in 3-D Spherical Coordinates 133 9.4 Summary 138 9.5 Appendix: Maple Code Listings 138 Problems 141 References 143 10 Diffusion-Controlled Ligand Binding to Receptors on Cell Surfaces 145 10.1 Weber’s Integral 145 10.2 Steady-State Diffusion-Limited Ligand Binding 148 10.3 Transient Diffusion-Controlled Ligand Binding in 2-D Cylindrical Coordinates 151 10.4 Summary 156 10.5 Appendix: Maple, Mathematica and Maxima Code Listings 156 Problems 167 References 168 11 Two-Dimensional Analysis of a Cylindrical Matrix Device with a Small Hole For Drug Release 169 11.1 Mathematical Modeling of Drug Transport through the Device 169 11.2 Drug Concentration Profile inside the Matrix 171 11.3 Normalized Cumulative Percentage of Drug Released 177 11.4 Summary 178 11.5 Appendix: Maple Code Listings 178 Problems 182 References 183 12 Three-Dimensional Drug Diffusion through Membranes from Distributed Sources 185 12.1 Governing Equations of the Transport Model 185 12.2 Analytical Solution of the Diffusion Model in 3-D Cartesian Systems 187 12.3 Average Dimensionless Concentration and Flux 194 12.4 Summary 194 12.5 Appendix: Maple and Mathematica Code Listings 195 Problems 207 References 207 13 Effective Time Constant for Two- and Three-Dimensional Controlled-Released Drug-Delivery Models 209 13.1 Effective Time Constant in Controlled-Release Drug-Delivery Systems 209 13.2 Intravitreal Drug Delivery using a 2-D Cylindrical Model 210 13.3 Analysis of a Rectangular Parallelepiped-Shaped Matrix with a Release Area 218 13.4 Summary 225 13.5 Appendix: Maple and Mathematica Code Listings 225 Problems 232 References 232 14 Data Fitting For Two- and Three-Dimensional Controlled- Release Drug-Delivery Models 233 14.1 Data Fitting in Controlled-Release Drug-Delivery Systems 233 14.2 Estimation of Diffusion Coefficient in a Solid Cylinder of Finite Length 234 14.3 Estimation of Diffusion Coefficient in a Rectangular Parallelepiped-Shaped Matrix 240 14.4 Summary 243 14.5 Appendix: Maple and Mathematica Code Listings 244 Problems 256 References 258 15 Optimization of Two- and Three-Dimensional Controlled-Released Drug-Delivery Models 259 15.1 Optimum Design of Controlled-Released Drug-Delivery Systems 259 15.2 Design of a 2-D Cylindrical Dosage Form with a Finite Mass Transfer Coefficient 260 15.3 Design of a Rectangular Parallelepiped-Shaped Matrix with a Finite Mass Transfer Coefficient 265 15.4 Summary 268 15.5 Appendix: Maple and Mathematica Code Listings 268 Problems 282 References 283 Index 285

Read more less

Book SynopsisPhytochemicals are naturally occurring bioactive compounds found in edible fruits, plants, vegetables, and herbs. Unlike vitamins and minerals, phytochemicals are not needed for the maintenance of cell viability, but they play a vital role in protecting neural cells from inflammation and oxidative stress associated with normal aging and acute and chronic age-related brain diseases.Neuroprotective Effects of Phytochemicals in Neurological Disordersexplores the advances in our understanding of the potential neuroprotective benefits that these naturally occurring chemicals contain. Neuroprotective Effects of Phytochemicals in Neurological Disordersexplores the role that a number of plant-based chemical compounds play in a wide variety of neurological disorders. Chapters explore the impact of phytochemicals on neurotraumatic disorders, such as stroke and spinal cord injury, alongside neurodegenerative diseases such as Alzheimer's and Parkinson's Disease, as well as neuropsychiatric disoTable of ContentsContributors xi Preface xix Acknowledgments xxiii 1 Use of Phytochemicals against Neuroinflammation 1Wei-Yi Ong, Tahira Farooqui, Christabel Fung-Yih Ho, Yee-Kong Ng, and Akhlaq A. Farooqui 2 Flavonoids in Transgenic Alzheimer’s Disease Mouse Models: Current Insights and Future Perspectives 43Angélica Maria Sabogal-Guáqueta, Edison Osorio, and Gloria Patricia Cardona-Gómez 3 Neuroprotective Effects of Polyphenols in Aging and Age-Related Neurological Disorders 65Giulia Corona and David Vauzour 4 Indian Herbs and their Therapeutic Potential against Alzheimer’s Disease 79Navrattan Kaur, Bibekananda Sarkar, Iqbal Gill, Sukhchain Kaur, Sunil Mittal, Monisha Dhiman, Prasad K. Padala, Regino Perez-Polo, and Anil K. Mantha 5 Garlic and its Effects in Neurological Disorders 113Akhlaq A. Farooqui and Tahira Farooqui 6 Effects of Extra-Virgin Olive Oil in Neurological Disorders 133Akhlaq A. Farooqui and Tahira Farooqui 7 Ginger Components as Anti-Alzheimer Drugs: Focus on Drug Design 149Faizul Azam 8 Phytomedicine: A Possible Tool for Alzheimer’s Disease Therapeutics 167Jai Malik 9 Effects of Phytochemicals on Diabetic Retinoneuropathy 199Mohammad Shamsul Ola, Mohd Imtiaz Nawaz, and Abdullah S. Alhomida 10 Herbal Drugs: A New Hope for Huntington’s Disease 213Jai Malik 11 Neuroprotective Properties of Dietary Polyphenols in Parkinson’s Disease 243Altaf S. Darvesh, McKenna McClure, Prabodh Sadana, Chris Paxos, Werner J. Geldenhuys, Joshua D. Lambert, Tariq M. Haqqi, and Jason R. Richardson 12 Potential of Polyphenols in the Treatment of Major Depression: Focus on Molecular Aspects 265Ashish Dhir 13 Effect of Phytochemicals on Diabetes-Related Neurological Disorders 283Abubakar Mohammed, Kanti Bhooshan Pandey, and Syed Ibrahim Rizvi 14 Neuroprotective Effects of Extra-Virgin Olive Oil and its Components in Alzheimer’s Disease 299Alaa H. Abuznait, Hisham Qosa, Loqman A. Mohamed, Yazan S. Batarseh, and Amal Kaddoumi 15 Protective Role of Black-Tea Extract in a Transgenic Drosophila Model of Parkinson’s Disease 317Yasir Hasan Siddique 16 Apitherapy: Therapeutic Effects of Propolis on Neurological Disorders 335Tahira Farooqui and Akhlaq A. Farooqui 17 Molecular Mechanisms behind the Beneficial Activity of Polyunsaturated Fatty Acids in Alzheimer’s Disease and Related Conditions 359Undurti N. Das 18 Prevention of Neuroinflammation by Resveratrol: Focus on Experimental Models and Molecular Mechanisms 377Justine Renaud and Maria-Grazia Martinoli 19 Modulation of the Estradiol and Neprilysin Pathways by Resveratrol in a Lipopolysaccharide Model of Cognitive Impairment 395Nesrine S. El Sayed 20 Neuroprotective Effect of Resveratrol in Cerebral Ischemia 407Ghosh Nilanjan, Ghosh Rituparna, Mandal C. Subhash, and Mahadeb Pal 21 Effects of Nobiletin in Animal Models of Cognitive Impairment: Current Insights and Future Perspectives 421Akira Nakajima, Yasushi Ohizumi, and Kiyofumi Yamada 22 Potential Neuroprotective Effects of Curcumin against Dementia 435Natascia Brondino, Laura Fusar-Poli, Cristina Panisi, and Pierluigi Politi 23 Neuroprotective Activity of Curcumin and Emblica officinalis Extract against Carbofuran-Induced Neurotoxicity in Wistar Rats 447Ramadasan Kuttan and P.P. Binitha 24 Potential Use of Curcuminoids for the Treatment of Alzheimer’s Disease 463Touqeer Ahmed, Sana Javed, Ameema Tariq, and Anwarul-Hassan Gilani 25 Prevention by Curcumin of Neuroinflammation in Intracerebral Hemorrhage 489Yujie Chen and Hua Feng 26 Effect of Polyphenols on Protein Misfolding 501Rona Banerjee 27 Molecular Mechanisms Involved in the Neuroprotective Action of Phytochemicals 515Aditya Sunkaria, Aarti Yadav, Sunil Kumar Sharma, and Rajat Sandhir 28 Nutraceuticals and Cognitive Dysfunction: Focus on Alzheimer’s Disease 561Virginia Boccardi, Clara Tinarelli, and Patrizia Mecocci 29 Summary and Perspective 581Tahira Farooqui and Akhlaq A. Farooqui Index 595

Read more less

Book SynopsisA peptidomimetic is a small protein-like chain designed to mimic a peptide with adjusted molecular properties such as enhanced stability or biological activity. It is a very powerful approach for the generation of small-molecule-based drugs as enzyme inhibitors or receptor ligands. Peptidomimetics in Organic and Medicinal Chemistry outlines the concepts and synthetic strategies underlying the building of bioactive compounds of a peptidomimetic nature. Topics covered include the chemistry of unnatural amino acids, peptide- and scaffold-based peptidomimetics, amino acid-side chain isosteres, backbone isosteres, dipeptide isosteres, beta-turn peptidomimetics, proline-mimetics as turn inducers, cyclic scaffolds, amino acid surrogates, and scaffolds for combinatorial chemistry of peptidomimetics. Case studies in the hit-to-lead process, such as the development of integrin ligands and thrombin inhibitors, illustrate the successful application of peptidomimetics in drug discoTable of ContentsPreface xiii Abbreviations xvii PART I The Basics of Peptidomimetics 1 1. The Basics of Peptidomimetics 3 1.1 Introduction 3 1.2 Definition and Classification 5 1.3 Strategic Approaches to Peptidomimetic Design 7 1.3.1 Modification of Amino Acids 8 1.3.2 Compounds with Global Restrictions 9 1.3.3 Molecular Scaffolds Mimicking the Peptidic Backbone 10 1.4 Successful Examples of Peptidomimetic Drugs 12 1.4.1 ACE Inhibitors 13 1.4.2 Thrombin Inhibitors 13 1.5 Conclusion 16 References 16 2. Synthetic Approaches towards Peptidomimetic Design 19 2.1 Introduction 19 2.2 Local Modifications 20 2.2.1 Single Amino Acid Modifications 23 2.2.2 Dipeptide Isosteres 26 2.2.3 Retro-inverso Peptides 29 2.2.4 N-Methylation of Peptides 30 2.2.5 Azapeptides 31 2.2.6 Peptoids 31 2.3 Global Restrictions through Cyclic Peptidomimetics 32 2.4 Peptidomimetic Scaffolds 34 2.5 Conclusions 35 References 35 PART II Synthetic Methods and Molecules 37 3. Peptidomimetic Bioisosteres 39 3.1 Introduction 39 3.2 Peptide Bond Isosteres 40 3.2.1 Thioamides 41 3.2.2 Esters 41 3.2.3 Alkenes and Fluoroalkenes 41 3.2.4 Transition-State Isosteres 42 3.3 Side-Chain Isosteres 45 3.3.1 Guanidine Isosteres in Arginine Peptidomimetics 45 3.3.2 Isosteres of Aspartic Acid and Glutamic Acid 49 3.3.3 Tethered α-Amino Acids: Constraining the χ-Space 53 3.4 Dipeptide Isosteres 59 3.4.1 δ-Amino Acids 63 3.5 Tripeptide Isosteres 67 3.6 Conclusion 68 References 69 4. Solid-Phase Synthesis and Combinatorial Approaches to Peptidomimetics 75 4.1 Introduction 75 4.2 Solid-Phase Synthesis of Peptidomimetics 76 4.2.1 Scaffolds from α-Amino Acids 76 4.2.2 Scaffolds from Amino Aldehyde Intermediates 85 4.2.3 Pyrrolidine-Containing Scaffolds 89 4.3 Conclusion 94 References 95 5. Click Chemistry: The Triazole Ring as a Privileged Peptidomimetic Scaffold 99 5.1 Introduction 99 5.1.1 CuAAC Reaction 100 5.1.2 Triazole Ring as a Peptidomimetic Isostere 101 5.2 Triazole-Containing Peptidomimetics Elaborated through ‘Click Chemistry’ 102 5.2.1 Macrocycles 102 5.2.2 Oligomers and Foldamers 107 5.3 Relevant Applications in Drug Discovery 110 5.3.1 AChE Inhibitors 110 5.3.2 HIV Protease Inhibitors 111 5.3.3 MMP Inhibitors 114 5.3.4 Integrin Ligands 115 5.4 Conclusions 118 Acknowledgements 119 References 119 6. Peptoids 123 6.1 Introduction and Basics of Peptoids 123 6.2 Synthetic Methods 126 6.3 Macrocyclic Peptoids 129 6.4 Conformational Analysis of Folded Peptoids 130 6.5 Application of Peptoids as Antimicrobial Peptidomimetics 132 6.6 Conclusions 134 References 134 7. Sugar Amino Acids 137 7.1 Introduction 137 7.2 α-SAAs 138 7.2.1 Furanoid α-SAAs 138 7.2.2 Pyranoid α-SAAs 142 7.3 β-SAAs 144 7.3.1 Furanoid β-SAAs 144 7.3.2 Pyranoid β-SAAs 147 7.4 γ-SAAs 148 7.5 δ-SAAs 150 7.5.1 Furanoid δ-SAAs 150 7.5.2 Pyranoid δ-SAAs 154 7.6 Representative Applications in Medicinal Chemistry 159 7.7 Conclusions 162 References 162 8. Cyclic -Amino Acids as Proline Mimetics 165 8.1 Introduction 165 8.2 Cyclic α-Amino Acids 166 8.2.1 3-Substituted Proline Derivatives 167 8.2.2 4-Substituted Proline Derivatives 168 8.2.3 5-Substituted Proline Derivatives 169 8.2.4 Other Heterocyclic Proline Analogues 171 8.3 Bicyclic α-Amino Acids 174 8.3.1 β/γ-Ring Junction 175 8.3.2 α/γ-Ring Junction 178 8.3.3 γ/δ-Ring Junction 179 8.3.4 α/δ-Ring Junction 180 8.3.5 β/δ-Ring Junction 182 8.3.6 N/β-Ring Junction 183 8.3.7 Pipecolic-Based Bicyclic α-Amino Acids 183 8.3.8 Morpholine-Based Bicyclic α-Amino Acids 187 8.4 Conclusions 189 References 189 9. -Turn Peptidomimetics 191 9.1 Introduction 191 9.2 Definition and Classification of β-Turns 192 9.3 Conformational Analysis 194 9.4 β-Turn Peptidomimetics 196 9.4.1 Proline Analogues in β-Turn Peptidomimetics 197 9.4.2 δ-Amino Acids as Reverse-Turn Inducers 200 9.4.3 Molecular Scaffolds as β-Turn Peptidomimetics 209 9.5 Conclusions 214 References 215 10. Peptidomimetic Foldamers 219 10.1 Introduction 219 10.2 Classification 220 10.3 Peptoids 221 10.4 β-Peptides: First Systematic Conformational Studies 221 10.5 Hybrid Foldamers 226 10.6 From Structural to Functional Foldamers 227 10.6.1 Peptoids as Foldameric Antimicrobial Peptidomimetics 227 10.6.2 Foldamers Targeting Bcl-xL Antiapoptotic Proteins 227 10.7 Conclusions 228 References 228 PART III Applications in Medicinal Chemistry 231 11. Case Study 1: Peptidomimetic HIV Protease Inhibitors 233 11.1 Introduction 233 11.2 The HIV-1 Virus 233 11.2.1 HIV-1 Protease 234 11.3 Antiretroviral Therapy 238 11.4 Drug Resistance 239 11.4.1 Mechanisms of Resistance to Protease Inhibitors 239 11.5 HIV-1 Protease Inhibitors 240 11.5.1 Transition-State Analogues 240 11.5.2 Peptidomimetic Drugs 241 11.5.3 Next-Generation Cyclic Peptidomimetic Inhibitors 245 11.6 Conclusions 255 Acknowledgements 255 References 256 12. Case Study 2: Peptidomimetic Ligands for Integrin 259 12.1 Introduction 259 12.2 Peptide-Based Peptidomimetic Integrin Ligands 262 12.3 Scaffold-Based Peptidomimetic Integrin Ligands 270 12.4 Conclusions 280 References 280 Index 283

Read more less

Book Synopsis

Read more less

Book Synopsis

Read more less

Book SynopsisCardiologists today prescribe medications with complex mechanisms of action, pharmacokinetics, indications, contraindications and drug-frug interactions; many of which were not available when today's practitioners were in training. This book was written to meet the growing demand for complete, detailed and accurate cardiac pharmacology information.Table of ContentsRon Waksman, Andrew E. Ajani. 0.0 Elective PCI. 0.1 Optimal antithrombotic therapy. 0.1.1 Unfractionated heparin and ACT monitoring. 0.1.2 Alternative to unfractionated heparin. 0.1.2.1 LMWH. 0.1.2.2 direct thrombin inhibitor (bivarlirudin). 0.1.2.3 direct Xa antagonist (fondaparinux). 0.2 Optimal antiplatelet therapy. 0.2.1 Dual aspirin and thienopyridine therapy. - pre-treatment and dose. 0.2.2 When to use GP2B3A inhibitor and which one to use. - abciximab, tirofiban, eptifibatide. 0.2.3 Duration of Antiplatelet therapy with drug-eluting vs. bare-metal stents. 1.0 High risk PCI. 1.1 ACS (non ST elevation). 1.1.1 Upstream GP2B3A inhibitors. 1.1.2 Timing, loading dose and duration of clopidogrel therapy. 1.2 Diabetes mellitus. 1.2.1 Peri-procedural management. 1.3 Renal dysfunction. 1.3.1 Renal protective agents. - IV hydration, N-acetylcysteine, bicarbonate, fenoldopam. - Timing, route of administration and duration. 1.3.2 Radiocontrast induced nephropathy. 1.3.2.1 Ideal contrast agent. 1.3.3 Additional risk with other medications. - ACE inhibitors, NSAIDS, hypotensive medications (e.g. nitrates, BBlockers). 1.4 Cardiogenic shock. 1.4.1 Inotropic support. - adrenaline, noradrenaline, dopamine, dobutamine, milrinone, levosimendan, metaraminol. - summary of when to use which agent (ref. ACC/AHA STEMI guidelines). 1.4.2 Anticoagulation support for mechanical devices. - IABP, LVAD, Tandem Heart, Impaler etc. 2.0 Acute STEMI PCI. 2.1 Primary. - summary of optimal anticoagulation, GP2B3A, antiplatelet therapy (aspirin, clopidogrel). 2.2 Rescue. - summary of optimal anticoagulation, GP2B3A, antiplatelet therapy (aspirin, clopidogrel). 2.3 Facilitated. - summary of optimal anticoagulation, GP2B3A and lytic combinations in recent trials. 2.4 Adjunctive therapies. 2.4.1 GIK (glucose-insulin-potassium). 2.4.2 Complement inhibitor (Pexiluzimab). 2.4.3 Intracoronary vs. intravenous GP2B3A inhibitor. 2.4.4 High dose tirofiban. (Standard dose GP2B3A inhibitors for STEMI discussed in 2.1 and 2.2). 3.0 Optimal thrombolytic therapy (as primary therapy for STEMI). - alteplase, reteplase, streptokinase, or tenecteplase. 4.0 Special considerations in PCI. 4.1 Coronary spasm. 4.2 No reflow phenomenon. - IV GTN, GP2B3A inhibitor, nitroprusside, adenosine, verapamil, nicorandil. 4.3 Agents to optimise access of radial artery approach (i.e. nitrates, verapamil). 4.4 Arrhythmia Management. 4.4.1 Tachyarrhythmias management. - IV lignocaine, amiodarone, etc. 4.4.2 Bradyarrhythmias management. - IV atropine, adrenalin, indications for temporary pacing wire. 4.5 Coronary perforations. 4.5.1 Reversal of anticoagulation. - protamine. 4.5.2 Platelet and transfusion of blood products. 4.6 Oral anticoagulation issues in PCI. 4.6.1 Management of patients on anticoagulation undergoing diagnostic catheterisation and PCI. - prosthetic heart valves, AF and other indications. - use of UFH and LMWH as bridging therapy. - when to restart oral anticoagulation post procedure. 4.6.2 Indications for anticoagulation post PCI. - LV thrombus. - large anterior myocardial infarction. - triple (aspirin, clopidogrel and warfarin) vs. dual therapy. 4.7 Role of Antibiotic prophylaxis in PCI. 5.0 Post procedural pharmacotherapy. 5.1 Role of statins, beta-blocker, ACE inhibitors, aldosterone antagonist (epleronone). 5.1.1 ACS (include STEMI/NSTEMI). 5.1.2 Elective PCI. 6.0 Special considerations with antiplatelet therapy. 6.1 Antiplatelet therapy resistance: definition, diagnosis and clinical implications. 6.2 Potential drug-drug interactions. 6.2.1 Clopidogrel and statins. 6.2.2 Aspirin and ibuprofen. 6.2.3 COX-2 inhibitors in patients with coronary artery disease. 6.3 Clopidogrel use in patients requiring CABGS. 6.4 Thrombocytopenia post PCI. 6.4.1 HITTS. 6.4.2 GP2B3A risk. 6.5 Novel antiplatelet therapy. - Prasugrel etc. 7.0 Pharmacotherapy for in-stent restenosis. 7.1 Drug-eluting stents. 7.1.1 Sirolimus. 7.1.2 Paclitaxel. 7.1.3 Other agents (ABT-578). 7.1.4 Oral agents to prevent ISR (Oral Sirolimus, Glitazones). 8.0 Novel pharmacotherapy and PCI. APPENDIX. - Listing of generic drug names in alphabetical order with 1 page summary sheet on each drug. o Indications and contraindications. o Dose and formulations. o Adverse reactions. o Drug interactions

Read more less

Book Synopsis

Read more less

Book Synopsis

Read more less

Book Synopsis

Read more less

Book SynopsisCommunication Skills for Pharmacists: Building Relationships, Improving Patient Care, third edition, includes new material that will help student pharmacists and practicing pharmacists develop the communication skills they need for providing high quality care. Effective relationships between pharmacists and patients and between pharmacists and physicians pave the way for positive treatment outcomes. To improve medication use and patient outcomes, pharmacists need skill in building these relationships. Key Features: 15 chapters from the second edition covering key communication skills for pharmacists: listening and empathic responding, supportive communication, persuasive communication, assertiveness, managing conflict, dealing with angry patients, and helping patients accept the behavior changes needed to manage their illness. A new chapter on communicating about sensitive medical issues (e.g., depression, erectile dysfunction) and a second new chapter on communicating with patients who have literacy limitations. A detailed patient counseling checklist to help pharmacists with the timing and organization of the information they provide to patients and the information they receive from patients. Dozens of examples of good and bad pharmacist–patient and pharmacist– physician dialogues. Questions for reflection at the end of each chapter. Table of Contents Introduction. 1. Caring, Covenants, Codes, and Commitment 2. Developing the Relationship 3. Choosing to See Patients as People 4. Listening and Empathic Responding 5. Patient Counseling 6. Managing the Angry Patient 7. Assertiveness 8. Conflict Management 9. Helping Patients with Change 10. Interacting with Physicians 11. Supportive Communication 12. Choosing an Appropriate Response 13. Persuasive Communication 14. Immediacy: How Word Choice and Nonverbal Cues Affect the Relationship 15. Cultural Competence 16. Communicating about Sensitive Issues 17. Communicating with Patients Who Have Literacy Limitations Index

Read more less

Book SynopsisLearning Pharmacology through Clinical Cases by Mario Babbini and Sandeep Bansal uniquely integrates the preclinical disciplines, which is crucial for pharmacological problem solving and learning to think critically. Each case portrays a real-life scenario, promoting a bridge from foundational knowledge to its application. A series of USMLE-style questions with thorough explanations guide the reader through a comprehensive understanding of relevant basic science disciplines such as physiology, pathology, and microbiology, followed by a detailed analysis of the pharmacology. Key Features Nearly 50 case studies mirror situations seen in every-day practice In-depth coverage of drugs in the context of specific disease states and clinical situations Comprehensive cases encompass medical/family/drug history, physical examination, lab findings, diagnosis, pharmacotherapy, and follow-up One set of multiple choice questions addresses related basic science content. A second set covers topics related to the pharmacology, such as mechanism of action, adverse effects, and contraindications. This essential, highly practical resource will help medical students build problem-solving skills, assess pharmacology knowledge, and fully prepare for board examinations.Table of Contents1 Acromegaly 2 Acute Lymphoblastic Leukemia 3 Asthma 4 Atrial Fibrillation 5 Bipolar Disorder 6 Breast Cancer 7 Cardiogenic Shock 8 Crohn's Disease 9 Chronic Kidney Disease 10 Chronic Obstructive Pulmonary Disease 11 Drug Abuse 12 Epilepsy 13 Essential Hypertension 14 General Anesthesia 15 Glaucoma 16 Gout 17 Graves' Disease 18 Growth Retardation and Hypogonadism 19 Heart Failure 20 Hematopoietic Cell Transplantation 21 Hodgkin's Lymphoma 22 Hormonal Contraception 23 Human Immunodeficiency Virus Infection 24 Infective Endocarditis 25 Iron Deficiency Anemia 26 Liver Cirrhosis 27 Lung Cancer 28 Megaloblastic Anemia 29 Migraine 30 Myasthenia Gravis 31 Myocardial Infarction 32 Parkinson's Disease 33 Peptic Ulcer Disease 34 Perimenopause and Osteoporosis 35 Pheochromocytoma 36 Pneumonia 37 Polycystic Ovarian Syndrome 38 Primary Adrenal Deficiency (Addison's Disease) 39 Prostate Cancer 40 Psoriasis 41 Pulmonary Embolism 42 Rheumatoid Arthritis 43 Schizophrenia 44 Solid Organ Transplantation 45 Stroke 46 Systemic Lupus Erythematosus 47 Torsade de Pointes 48 Type 1 Diabetes Mellitus 49 Type 2 Diabetes Mellitus 50 Urinary Tract Infection

Read more less

Book Synopsis

Read more less

Book Synopsis

Read more less